BioLineRx (NASDAQ:BLRX) Price Target Raised to $26.00 at HC Wainwright

BioLineRx (NASDAQ:BLRX) had its price target increased by HC Wainwright from $9.00 to $26.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Separately, StockNews.com downgraded BioLineRx from a “hold” rating to a “sell” rating in a research report on Tuesday, March 18th.

BioLineRx Price Performance

Shares of BioLineRx stock opened at $2.96 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. BioLineRx has a 52 week low of $2.88 and a 52 week high of $44.00. The stock’s 50-day simple moving average is $3.53 and its 200-day simple moving average is $10.77. The company has a market capitalization of $9.85 million, a price-to-earnings ratio of -0.34 and a beta of 1.39.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new position in BioLineRx Ltd. (NASDAQ:BLRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx at the end of the most recent quarter. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.